Skip to main content

Advertisement

Table 1 Patient characteristics

From: The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization

Metastatic breast cancer  
 No. of patients enrolled—100  
 Age, years  Hormone receptor status
  Median, range 59 (66–81)   ER-positive/PR-positive—45 (45%)
 ECOG performance status   ER-positive/PR-negative—16 (16%)
    ER-negative/PR-positive—5 (5%)
  0—66 (66%)   ER-negative/PR-negative—18 (18%)
  1—23 (23%)   Unknown—16 (16%)
  2—6 (6%)  No. of disease sites
  Unknown—5 (5%)   1—51 (51%)
 Histology   2—21 (21%)
  Ductal—75(75%)   3—11 (11%)
  Lobular—10 (10%)   ≥ 4—2 (2%)
  Other—9(9%)   Unknown—15 (15%)
  Unknown—6 (6%)  Visceral disease
 Menopausal status   Yes—37 (37%)
  Premenopausal—26 (26%)   No—50 (50%)
  Perimenopausal—12 (12%)   Unknown—13 (13%)
  Postmenopausal—53 (53%)  Triple negative (ER negPRnegHER2neg)
  Unknown—9 (9%)   11 (11%)
 HER2 status  
  HER2 negative—64 (64%)  
  Her2 positive—18 (18%)  
  Unknown—18 (18%)